These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38474192)

  • 1. Update on Antioxidant Therapy with Edaravone: Expanding Applications in Neurodegenerative Diseases.
    Yamashita T; Abe K
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Research and development of the free radical scavenger edaravone as a neuroprotectant].
    Watanabe T; Tanaka M; Watanabe K; Takamatsu Y; Tobe A
    Yakugaku Zasshi; 2004 Mar; 124(3):99-111. PubMed ID: 15049127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Edaravone for the treatment of amyotrophic lateral sclerosis.
    Yoshino H
    Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients.
    Park JM; Kim SY; Park D; Park JS
    Neurol Sci; 2020 Jan; 41(1):119-123. PubMed ID: 31471712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent].
    Tanaka M
    Nihon Yakurigaku Zasshi; 2002 May; 119(5):301-8. PubMed ID: 12061142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
    Bhandari R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse.
    Ikeda K; Iwasaki Y
    PLoS One; 2015; 10(10):e0140316. PubMed ID: 26469273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Edaravone May Prevent Ferroptosis in ALS.
    Spasić S; Nikolić-Kokić A; Miletić S; Oreščanin-Dušić Z; Spasić MB; Blagojević D; Stević Z
    Curr Drug Targets; 2020; 21(8):776-780. PubMed ID: 32077821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antioxidants and neuroprotection in the adult and developing central nervous system.
    Kaur C; Ling EA
    Curr Med Chem; 2008; 15(29):3068-80. PubMed ID: 19075654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion.
    Brooks BR; Jorgenson JA; Newhouse BJ; Shefner JM; Agnese W
    Am J Manag Care; 2018 Apr; 24(9 Suppl):S175-S186. PubMed ID: 29693363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Edaravone: A Novel Possible Drug for Cancer Treatment?
    Duranti E; Cordani N; Villa C
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury.
    Yoshida H; Yanai H; Namiki Y; Fukatsu-Sasaki K; Furutani N; Tada N
    CNS Drug Rev; 2006; 12(1):9-20. PubMed ID: 16834755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats.
    Zhou S; Yu G; Chi L; Zhu J; Zhang W; Zhang Y; Zhang L
    Neurotoxicology; 2013 Sep; 38():136-45. PubMed ID: 23932983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does edaravone (MCI- 186) act as an antioxidant and a neuroprotector in experimental traumatic brain injury?
    Dohi K; Satoh K; Nakamachi T; Yofu S; Hiratsuka K; Nakamura S; Ohtaki H; Yoshikawa T; Shioda S; Aruga T
    Antioxid Redox Signal; 2007 Feb; 9(2):281-7. PubMed ID: 17115943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers.
    Green AR; Ashwood T
    Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):109-18. PubMed ID: 15857295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis Patients in Indian Population.
    Tomar S; Gupta S; Singal A; Soni R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study.
    Park JM; Park D; Kim HJ; Park JS
    BMC Neurol; 2022 Jul; 22(1):260. PubMed ID: 35836136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases.
    Higashi Y; Jitsuiki D; Chayama K; Yoshizumi M
    Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):85-93. PubMed ID: 18221078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Edaravone and its clinical development for amyotrophic lateral sclerosis.
    Takei K; Watanabe K; Yuki S; Akimoto M; Sakata T; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):5-10. PubMed ID: 28872907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced oxidative stress and the treatment by edaravone in mice model of amyotrophic lateral sclerosis.
    Ohta Y; Nomura E; Shang J; Feng T; Huang Y; Liu X; Shi X; Nakano Y; Hishikawa N; Sato K; Takemoto M; Yamashita T; Abe K
    J Neurosci Res; 2019 May; 97(5):607-619. PubMed ID: 30565312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.